6-Bromo-8-methyl-2-(3-(naphthalen-1-yl)-1H-pyrazol-4-yl)-2,3-dihydroquinazolin-4(1H)-one

ID: ALA4176916

Chembl Id: CHEMBL4176916

PubChem CID: 145972219

Max Phase: Preclinical

Molecular Formula: C22H17BrN4O

Molecular Weight: 433.31

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(Br)cc2c1NC(c1c[nH]nc1-c1cccc3ccccc13)NC2=O

Standard InChI:  InChI=1S/C22H17BrN4O/c1-12-9-14(23)10-17-19(12)25-21(26-22(17)28)18-11-24-27-20(18)16-8-4-6-13-5-2-3-7-15(13)16/h2-11,21,25H,1H3,(H,24,27)(H,26,28)

Standard InChI Key:  HMTOXAAOXBALFX-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4176916

    ---

Associated Targets(Human)

TRPM2 Tchem Transient receptor potential cation channel subfamily M member 2 (348 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TRPM8 Tclin Transient receptor potential cation channel subfamily M member 8 (1168 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 433.31Molecular Weight (Monoisotopic): 432.0586AlogP: 5.15#Rotatable Bonds: 2
Polar Surface Area: 69.81Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.02CX Basic pKa: 2.20CX LogP: 5.66CX LogD: 5.66
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.41Np Likeness Score: -0.86

References

1. Zhang H, Liu H, Luo X, Wang Y, Liu Y, Jin H, Liu Z, Yang W, Yu P, Zhang L, Zhang L..  (2018)  Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.,  152  [PMID:29723786] [10.1016/j.ejmech.2018.04.045]
2. Zhang H, Yu P, Lin H, Jin Z, Zhao S, Zhang Y, Xu Q, Jin H, Liu Z, Yang W, Zhang L..  (2021)  The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.,  64  (7.0): [PMID:33784097] [10.1021/acs.jmedchem.0c02129]

Source